NCT01507389View on ClinicalTrials.gov

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Single dose of 0.75 mg injected subcutaneously (under the skin)

Trial Locations (1)

01-201

Warsaw

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01507389 - Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function | Biotech Hunter | Biotech Hunter